These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor. Trtková K; Pašková L; Matiješčuková N; Kolář Z Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266 [TBL] [Abstract][Full Text] [Related]
25. Identification of pyridazin-3-one derivatives as potent, selective histamine H₃ receptor inverse agonists with robust wake activity. Hudkins RL; Aimone LD; Bailey TR; Bendesky RJ; Dandu RR; Dunn D; Gruner JA; Josef KA; Lin YG; Lyons J; Marcy VR; Mathiasen JR; Sundar BG; Tao M; Zulli AL; Raddatz R; Bacon ER Bioorg Med Chem Lett; 2011 Sep; 21(18):5493-7. PubMed ID: 21782432 [TBL] [Abstract][Full Text] [Related]
26. Androgen receptor regulates Cdc6 in synchronized LNCaP cells progressing from G1 to S phase. Bai VU; Cifuentes E; Menon M; Barrack ER; Reddy GP J Cell Physiol; 2005 Aug; 204(2):381-7. PubMed ID: 15887248 [TBL] [Abstract][Full Text] [Related]
27. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity. Wang LG; Liu XM; Kreis W; Budman DR Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909 [TBL] [Abstract][Full Text] [Related]
28. Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. Buchanan G; Ricciardelli C; Harris JM; Prescott J; Yu ZC; Jia L; Butler LM; Marshall VR; Scher HI; Gerald WL; Coetzee GA; Tilley WD Cancer Res; 2007 Oct; 67(20):10087-96. PubMed ID: 17942943 [TBL] [Abstract][Full Text] [Related]
29. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells. Bass R; Perry B; Langenstroer P; Thrasher JB; Dennis KL; Tawfik O; Holzbeierlein J J Urol; 2009 Feb; 181(2):615-9; discussion 619-20. PubMed ID: 19091346 [TBL] [Abstract][Full Text] [Related]
30. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446 [TBL] [Abstract][Full Text] [Related]
31. Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists. Xiao HY; Balog A; Attar RM; Fairfax D; Fleming LB; Holst CL; Martin GS; Rossiter LM; Chen J; Cvjic ME; Dell-John J; Geng J; Gottardis MM; Han WC; Nation A; Obermeier M; Rizzo CA; Schweizer L; Spires T; Shan W; Gavai A; Salvati ME; Vite G Bioorg Med Chem Lett; 2010 Aug; 20(15):4491-5. PubMed ID: 20584610 [TBL] [Abstract][Full Text] [Related]
32. A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model. Saleem M; Kweon MH; Yun JM; Adhami VM; Khan N; Syed DN; Mukhtar H Cancer Res; 2005 Dec; 65(23):11203-13. PubMed ID: 16322271 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Eder IE; Culig Z; Ramoner R; Thurnher M; Putz T; Nessler-Menardi C; Tiefenthaler M; Bartsch G; Klocker H Cancer Gene Ther; 2000 Jul; 7(7):997-1007. PubMed ID: 10917202 [TBL] [Abstract][Full Text] [Related]
34. Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells. Makkonen H; Kauhanen M; Jääskeläinen T; Palvimo JJ Mol Cell Endocrinol; 2011 Jan; 331(1):57-65. PubMed ID: 20728506 [TBL] [Abstract][Full Text] [Related]
35. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Jiang C; Lee HJ; Li GX; Guo J; Malewicz B; Zhao Y; Lee EO; Lee HJ; Lee JH; Kim MS; Kim SH; Lu J Cancer Res; 2006 Jan; 66(1):453-63. PubMed ID: 16397261 [TBL] [Abstract][Full Text] [Related]
36. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate. Middleman MN; Lush RM; Figg WD Pharmacotherapy; 1996; 16(3):376-81. PubMed ID: 8726595 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor. Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333 [TBL] [Abstract][Full Text] [Related]
38. Cross-talk between androgen receptor and pregnane and xenobiotic receptor reveals existence of a novel modulatory action of anti-androgenic drugs. Kumar S; Jaiswal B; Kumar S; Negi S; Tyagi RK Biochem Pharmacol; 2010 Oct; 80(7):964-76. PubMed ID: 20599793 [TBL] [Abstract][Full Text] [Related]
39. Discovery of potent and muscle selective androgen receptor modulators through scaffold modifications. Li JJ; Sutton JC; Nirschl A; Zou Y; Wang H; Sun C; Pi Z; Johnson R; Krystek SR; Seethala R; Golla R; Sleph PG; Beehler BC; Grover GJ; Fura A; Vyas VP; Li CY; Gougoutas JZ; Galella MA; Zahler R; Ostrowski J; Hamann LG J Med Chem; 2007 Jun; 50(13):3015-25. PubMed ID: 17552509 [TBL] [Abstract][Full Text] [Related]
40. Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR). Berrevoets CA; Umar A; Trapman J; Brinkmann AO Biochem J; 2004 May; 379(Pt 3):731-8. PubMed ID: 14744261 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]